Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942672 | 0.90 | NR1H4 (0.55) | KDM4EPTGDR2KMT2ANPC1RAB9A | |
| SCHEMBL2941686 | 0.87 | PTGDR2 (0.56) | PTGDR2CTNNB1TCF7L2 | |
| SCHEMBL2939746 | 0.85 | KDM4E (0.56) | KDM4EPTGDR2MEN1KMT2AKCNQ3 | |
| SCHEMBL2942781 | 0.79 | PTGDR2 (0.36) | KDM4EPTGDR2MEN1KMT2AHPGD | |
| SCHEMBL2948450 | 0.78 | PTGDR2 (0.51) | PTGDR2NPC1RAB9A | |
| SCHEMBL2948452 | 0.78 | PTGDR2 (0.51) | PTGDR2NPC1RAB9A | |
| SCHEMBL13236209 | 0.78 | PTGDR2 (0.47) | PTGDR2SMN1; SMN2CTNNB1TCF7L2MAPT | |
| SCHEMBL13236240 | 0.77 | PTGDR2 (0.47) | KDM4EPTGDR2MEN1KMT2AALDH1A1 | |
| SCHEMBL2946919 | 0.77 | PTGDR2 (0.54) | KDM4EPTGDR2MEN1KMT2AALDH1A1 | |
| SCHEMBL2946922 | 0.77 | PTGDR2 (0.54) | KDM4EPTGDR2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | claimed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | claimed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | claimed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | claimed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | KDM4E 4745/4885PTGDR2 56/4885MEN1 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.